Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain

Background: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and increased healthcare costs. IDA is treated with iron supplementation, commonly with intravenous iron formulations, such as ferric carboxymaltose (FCM),...

Descripción completa

Detalles Bibliográficos
Autores: Argüelles Arias, Federico, Bermejo, Fernando, Borrás-Blasco, Joaquín, Domènech, Eugeni, Sicilia, Beatriz, Huguet, José M., Ramírez de Arellano, Antonio, Valentine, William J., Hunt, Barnaby
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/140175
Acceso en línea:https://hdl.handle.net/11441/140175
https://doi.org/10.1177/17562848221086131
Access Level:acceso abierto
Palabra clave:Cost
Cost-effectiveness
Inflammatory bowel disease
Iron deficiency anemia
id ES_7c8eaeb507d43e3a268863f286501271
oai_identifier_str oai:idus.us.es:11441/140175
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in SpainArgüelles Arias, FedericoBermejo, FernandoBorrás-Blasco, JoaquínDomènech, EugeniSicilia, BeatrizHuguet, José M.Ramírez de Arellano, AntonioValentine, William J.Hunt, BarnabyCostCost-effectivenessInflammatory bowel diseaseIron deficiency anemiaBackground: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and increased healthcare costs. IDA is treated with iron supplementation, commonly with intravenous iron formulations, such as ferric carboxymaltose (FCM), and iron sucrose (IS). Methods: This study assessed the cost-effectiveness of FCM compared with IS, in terms of additional cost per additional responder in patients with IDA subsequent to IBD in the Spanish setting. An economic model was developed to assess the additional cost per additional responder, defined as normalization or an increase of ⩾2g/dl in hemoglobin levels, for FCM versus IS from a Spanish healthcare payer perspective. Efficacy inputs were taken from a randomized controlled trial comparing the two interventions (FERGIcor). Costs of treatment were calculated in 2021 Euros (EUR) using a microcosting approach and included the costs of intravenous iron, healthcare professional time, and consumables. Cost-effectiveness was assessed over one cycle of treatment, with a series of sensitivity analyses performed to test the robustness of the results. Results: FCM was more effective than IS, with 84% of patients achieving a response compared with 76%. When expressed as number needed to treat, 13 patients would need to switch treatment from IS to FCM in order to achieve one additional responder. Costs of treatment were EUR 323 with FCM compared with EUR 470 with IS, a cost saving of EUR 147 with FCM. Cost savings with FCM were driven by the reduced number of infusions required, resulting in a reduced requirement for healthcare professional time and use of consumables compared with the IS arm. Conclusion: The present analysis suggests that FCM is less costly and more effective than IS for the treatment of IDA subsequent to IBD in Spain and therefore was considered dominant.Sage PublishingMedicina2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/140175https://doi.org/10.1177/17562848221086131reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésTherapeutic Advances in Gastroenterology, 15, 167-12.https://journals.sagepub.com/doi/10.1177/17562848221086131info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1401752026-06-17T12:51:07Z
dc.title.none.fl_str_mv Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
title Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
spellingShingle Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
Argüelles Arias, Federico
Cost
Cost-effectiveness
Inflammatory bowel disease
Iron deficiency anemia
title_short Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
title_full Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
title_fullStr Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
title_full_unstemmed Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
title_sort Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
dc.creator.none.fl_str_mv Argüelles Arias, Federico
Bermejo, Fernando
Borrás-Blasco, Joaquín
Domènech, Eugeni
Sicilia, Beatriz
Huguet, José M.
Ramírez de Arellano, Antonio
Valentine, William J.
Hunt, Barnaby
author Argüelles Arias, Federico
author_facet Argüelles Arias, Federico
Bermejo, Fernando
Borrás-Blasco, Joaquín
Domènech, Eugeni
Sicilia, Beatriz
Huguet, José M.
Ramírez de Arellano, Antonio
Valentine, William J.
Hunt, Barnaby
author_role author
author2 Bermejo, Fernando
Borrás-Blasco, Joaquín
Domènech, Eugeni
Sicilia, Beatriz
Huguet, José M.
Ramírez de Arellano, Antonio
Valentine, William J.
Hunt, Barnaby
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Medicina
dc.subject.none.fl_str_mv Cost
Cost-effectiveness
Inflammatory bowel disease
Iron deficiency anemia
topic Cost
Cost-effectiveness
Inflammatory bowel disease
Iron deficiency anemia
description Background: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and increased healthcare costs. IDA is treated with iron supplementation, commonly with intravenous iron formulations, such as ferric carboxymaltose (FCM), and iron sucrose (IS). Methods: This study assessed the cost-effectiveness of FCM compared with IS, in terms of additional cost per additional responder in patients with IDA subsequent to IBD in the Spanish setting. An economic model was developed to assess the additional cost per additional responder, defined as normalization or an increase of ⩾2g/dl in hemoglobin levels, for FCM versus IS from a Spanish healthcare payer perspective. Efficacy inputs were taken from a randomized controlled trial comparing the two interventions (FERGIcor). Costs of treatment were calculated in 2021 Euros (EUR) using a microcosting approach and included the costs of intravenous iron, healthcare professional time, and consumables. Cost-effectiveness was assessed over one cycle of treatment, with a series of sensitivity analyses performed to test the robustness of the results. Results: FCM was more effective than IS, with 84% of patients achieving a response compared with 76%. When expressed as number needed to treat, 13 patients would need to switch treatment from IS to FCM in order to achieve one additional responder. Costs of treatment were EUR 323 with FCM compared with EUR 470 with IS, a cost saving of EUR 147 with FCM. Cost savings with FCM were driven by the reduced number of infusions required, resulting in a reduced requirement for healthcare professional time and use of consumables compared with the IS arm. Conclusion: The present analysis suggests that FCM is less costly and more effective than IS for the treatment of IDA subsequent to IBD in Spain and therefore was considered dominant.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/140175
https://doi.org/10.1177/17562848221086131
url https://hdl.handle.net/11441/140175
https://doi.org/10.1177/17562848221086131
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Therapeutic Advances in Gastroenterology, 15, 167-12.
https://journals.sagepub.com/doi/10.1177/17562848221086131
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Sage Publishing
publisher.none.fl_str_mv Sage Publishing
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411599131869184
score 15,301603

Similares en LA Referencia